Latest On Roche Holding AG (RHHBY):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-03-14 06:01 EST | Dividend | A dividend of $1.39 has been announced on Feb 2, 2024. It will be paid Nov 30, -0001 with an ex-dividend date of Mar 14, 2024. | Neutral |  |
| 2023-05-26 18:42 EST | News | Roche drives rival anti-TIGIT developers higher after cancer drug data | N/A | |
| 2023-04-05 14:49 EST | News | Democratic senators urge U.S. to maintain free COVID tests under Medicare | N/A | |
| 2023-03-22 19:34 EST | News | Novartis, Genentech tout long-term data on muscular atrophy therapies | N/A | |
| 2023-03-16 05:56 EST | Dividend | A dividend of $1.29 has been announced on Feb 2, 2023. It will be paid Mar 27, 2023 with an ex-dividend date of Mar 16, 2023. | Neutral | |
| 2023-03-08 18:10 EST | News | Roche: Ongoing Pipeline Issues Sap Growth And Increase M&A Likelihood | N/A | |
| 2023-03-06 06:43 EST | News | Roche receives FDA approval of label expansion for VENTANA PD-L1 | N/A | |
| 2023-03-02 08:58 EST | News | Chugai, Biofourmis expand team up on digital solutions to measure endometriosis pain | N/A | |
| 2023-01-06 18:30 EST | News | Lilly, Anavex, other Alzheimer's drug developers rise modestly on Biogen lecanemab approval | N/A | |
| 2022-12-30 16:08 EST | News | Roche: Worthy Of Big Pharma Label, Maybe Not A 'Value Pick' Yet | N/A | |
| 2022-12-24 23:44 EST | News | Stocks To Watch: Nio, Tesla And Hopes For A Santa Clause Rally | N/A | |
| 2022-12-10 02:29 EST | News | Roche's Tecentriq receives additional indication from FDA for alveolar sarcoma | N/A | |
| 2022-12-07 03:37 EST | News | Bad flu season turned even worse around Thanksgiving - CDC | N/A | |
| 2022-11-16 20:22 EST | News | Pfizer, Roche, Lilly COVID treatments get draft recommendation from UK NHS advisors | N/A | |
| 2022-11-14 17:44 EST | News | Cassava, Biogen lead Alzheimer's stocks higher following Roche's gantenerumab setback | N/A | |
| 2022-11-05 04:02 EST | News | Fewer Americans have received the flu shot compared to same time last year - CDC | N/A | |
| 2022-11-01 17:52 EST | News | Roche Needs Some Wins | N/A | |
| 2022-10-28 23:23 EST | News | Flu season off to a strong and early start, CDC data finds | N/A | |
| 2022-10-06 18:44 EST | News | Bipartisan bill aims to get CMS to cover Alzheimer's antibody treatments | N/A | |
| 2022-09-29 17:50 EST | News | Biogen, Eisai cool off after massive run-up following lecanemab Alzheimer's data | N/A | |
| 2022-09-20 07:28 EST | News | Roche wins FDA clearance for cobas lab work area platform | N/A | |
| 2022-09-08 20:01 EST | News | Roche upgraded at Jefferies citing favorable risk reward | N/A | |
| 2022-08-29 20:49 EST | News | Biden administration ending free at-home COVID tests due to lack of funding | N/A | |
| 2022-08-04 03:58 EST | News | Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics | N/A | |
| 2022-07-25 20:27 EST | News | Roche Holding Non-GAAP EPS of CHF11.76, revenue of CHF32.3B | N/A | |
| 2022-07-22 07:35 EST | News | Scientist casts doubt on amyloid theory for Alzheimer's; sees issues with Cassava images | N/A | |
| 2022-07-15 05:29 EST | News | Roche touts long-term data of Perjeta combination therapy for breast cancer | N/A | |
| 2022-07-14 13:44 EST | News | Data bolsters long-term efficacy of Genentech's Vabysmo for macular degeneration | N/A | |
| 2022-07-13 08:16 EST | News | Amgen Lumakras combination data in lung cancer held until August - Reuters | N/A | |
| 2022-07-12 03:03 EST | News | Roche licenses nephropathy treatment from Ionis and conduct late-stage study | N/A | |
| 2022-07-03 00:14 EST | News | As amyloid-targeting therapies for Alzheimer's fail, where might success lie? | N/A | |
| 2022-06-15 17:40 EST | News | Roche wins FDA nod for COVID-19 test that can also detect viral load | N/A | |
| 2022-05-28 19:50 EST | News | ASCO 2022: What investors should pay attention to at the year's biggest medical meeting | N/A | |
| 2022-05-28 04:20 EST | News | Genetech's glofitamab demonstrates durable complete response in large B-cell lymphoma | N/A | |
| 2022-05-26 02:55 EST | News | Roche wins EC approval of Polivy as first-line treatment for large B-cell lymphoma | N/A | |
| 2022-05-26 02:55 EST | News | Roche develops PCR tests to detect monkeypox | N/A | |
| 2022-04-29 15:21 EST | News | Genentech's Evrysdi shows long-term improvements in spinal muscular atrophy patients | N/A | |
| 2022-04-25 13:07 EST | News | Roche multiple sclerosis drug development impacted by Russia/Ukraine conflict | N/A | |
| 2022-04-20 05:50 EST | News | FDA issues warning on potential false results from noninvasive prenatal screening tests | N/A | |
| 2022-04-10 05:52 EST | News | How might the CMS decision on Biogen's Aduhelm impact other Alzheimer's candidates? | N/A | |
| 2022-04-08 07:16 EST | News | Biogen lower as Medicare officially limits coverage for Alzheimer’s drug | N/A | |
| 2022-03-18 03:44 EST | News | AstraZeneca to pay $775M to Roche's unit Chugai to settle Ultomiris patent litigation | N/A | |
| 2022-03-17 05:56 EST | Dividend | A dividend of $1.26 has been announced on Feb 3, 2022. It will be paid Mar 28, 2022 with an ex-dividend date of Mar 17, 2022. | Neutral | |
| 2022-03-14 02:47 EST | News | Biogen awaits Medicare decision on Alzheimer’s drug amid public pressure for coverage | N/A | |
| 2022-02-23 08:24 EST | News | Warning: RHHBY is at high risk of cutting their dividend | N/A | |
| 2022-02-22 13:15 EST | News | Roche Knocked Back A Bit Ahead Of A Year Of Important Read-Outs | N/A | |
| 2022-02-18 04:19 EST | News | Roche Diagnostics wins $212.5M Army modification contract | N/A | |
| 2022-02-12 07:06 EST | News | Roche arthritis drug added to WHO list of COVID-19 medicines | N/A | |
| 2022-02-03 20:11 EST | News | Roche sets 2022 guidance amid falling demand for COVID-related products | N/A | |
| 2022-02-03 03:42 EST | News | Roche Holding FY 2021 Earnings Preview | N/A | |
About Roche Holding AG (RHHBY):
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.
General
- Name Roche Holding AG
- Symbol RHHBY
- Type Common Stock
- Exchange OTCQX
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-General
- Full Time Employees 101,465
- Last Split Factor2:1
- Last Split Date2014-02-27
- Fiscal Year EndDecember
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.roche.com
View More
Valuation
- Trailing PE 21.54
- Forward PE 14.75
- Price/Sales (Trailing 12 Mt.) 4.53
- Price/Book (Most Recent Quarter) 7.17
- Enterprise Value Revenue 5.01
- Enterprise Value EBITDA 12.67
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 24%
- Return on Assets 15%
- Return on Equity 40%
- Earnings Per Share $1.54
- Revenue Per Share $0
- Gross Profit 44.48 billion
- Quarterly Earnings Growth -6.4%
View More
Highlights
- Market Capitalization 278.52 billion
- PE Ratio 12.93
- PEG Ratio 2.91
- Analyst Target Price $48.51
- Book Value Per Share $4.04
View More
Share Statistics
- Shares Outstanding 6.83 billion
- Shares Float 5.75 billion
- % Held by Insiders <1%
- % Held by Institutions 1.52%
View More
Technicals
- Beta 0.21
- 52 Week High $47.15
- 52 Week Low $35.04
- 50 Day Moving Average 42.24
- 200 Day Moving Average 43.01
View More
Dividends
- Forward Annual Dividend Rate $1.28
- Forward Annual Dividend Yield 3.01%
- Payout Ratio 9%
- Dividend Date 2021-03-29
- ExDividend Date 2021-03-18
- Dividend Per Share $1.28
- Dividend Yield 0%
View More
Roche Holding AG (RHHBY) Dividend Calendar:
RHHBY's last dividend payment was made to shareholders on March 29, 2021.
Roche Holding AG pays out 9% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|---|---|---|---|
| 2023-03-16 | 2023-03-27 | 2023-03-17 | 2023-02-02 | $1.29 |
| 2022-03-17 | 2022-03-28 | 2022-03-18 | 2022-02-03 | $1.26 |
| 2021-03-18 | 2021-03-29 | 2021-03-19 | 0000-00-00 | $1.28 |
| 2020-03-19 | 2020-03-30 | 2020-03-20 | $1.15 | |
| 2019-03-07 | 2019-03-18 | 2019-03-08 | $1.07 | |
| 2018-03-15 | 2018-05-04 | 2018-03-16 | $1.08 | |
| 2017-03-15 | 2017-05-11 | 2017-03-17 | $1.03 | |
| 2016-03-02 | 2016-04-22 | 2016-03-04 | $1.02 | |
| 2015-03-04 | 2015-04-20 | 2015-03-06 | 2015-02-03 | $1 |
| 2024-03-14 | 0000-00-00 | 2024-03-15 | 2024-02-02 | $1.39 |
Roche Holding AG (RHHBY) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | $4.06 | $0.00 | |
| 2020-06-30 | 2020-09-30 | $N/A | $3.90 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $N/A | $4.92 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $16.53 billion | $4.85 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $16.03 billion | $2.91 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $16.22 billion | $2.82 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $15.89 billion | $5.11 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $15.27 billion | $5.01 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $15.23 billion | $1.89 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $14.86 billion | $1.89 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $15.45 billion | $4.30 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $28.51 billion | $4.46 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $14.1 billion | $1.88 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $28.74 billion | $1.89 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $13.77 billion | $3.32 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $25.25 billion | $3.18 | $0.00 | |
| 2016-09-30 | 2016-12-31 | $N/A | $2.40 | $0.00 | |
| 2016-06-30 | 2016-09-30 | $26.56 billion | $2.52 | $0.00 | |
| 2016-03-31 | 2016-06-30 | $N/A | $3.20 | $0.00 | |
| 2015-12-31 | 2016-03-31 | $23.75 billion | $3.26 | $0.00 | |
| 2015-09-30 | 2015-12-31 | $N/A | $2.15 | $0.00 | |
| 2015-06-30 | 2015-09-30 | $26.57 billion | $2.20 | $0.00 | |
| 2015-03-31 | 2015-06-30 | $N/A | $3.19 | $0.00 | |
| 2014-12-31 | 2015-03-31 | $22.77 billion | $3.08 | $0.00 | |
| 2014-09-30 | 2014-12-31 | $N/A | $2.22 | $0.00 | |
| 2014-06-30 | 2014-09-30 | $27 billion | $2.30 | $0.00 | |
| 2014-03-31 | 2014-06-30 | $N/A | $3.61 | $0.00 | |
| 2013-12-31 | 2014-03-31 | $28.93 billion | $3.63 | $0.00 | |
| 2013-09-30 | 2013-12-31 | $N/A | $3.40 | $0.00 | |
| 2013-06-30 | 2013-09-30 | $25.66 billion | $3.35 | $0.00 | |
| 2013-03-31 | 2013-06-30 | $N/A | $3.63 | $0.00 | |
| 2012-12-31 | 2013-03-31 | $27.25 billion | $3.62 | $0.00 | |
| 2012-09-30 | 2012-12-31 | $N/A | $3.33 | $0.00 | |
| 2012-06-30 | 2012-09-30 | $24.57 billion | $3.24 | $0.00 | |
| 2012-03-31 | 2012-06-30 | $N/A | $2.60 | $0.00 | |
| 2011-12-31 | 2012-03-31 | $20.35 billion | $2.73 | $0.00 | |
| 2011-09-30 | 2011-12-31 | $N/A | $2.64 | $0.00 | |
| 2011-06-30 | 2011-09-30 | $26.71 billion | $2.73 | $0.00 | |
| 2011-03-31 | 2011-06-30 | $N/A | $3.59 | $0.00 | |
| 2010-12-31 | 2011-03-31 | $28.8 billion | $3.30 | $0.00 | |
| 2010-09-30 | 2010-12-31 | $N/A | $2.00 | $0.00 | |
| 2006-12-31 | 2007-02-07 | $19.63 billion | $0.46 | $0.48 | -4.17% |
| 2006-06-30 | 2006-08-15 | $16.04 billion | $0.45 | $0.45 | 0% |
| 2005-12-31 | 2006-02-01 | $14.6 billion | $0.35 | $0.30 | 16.67% |
Roche Holding AG (RHHBY) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Roche Holding AG (RHHBY) Chart:
Roche Holding AG (RHHBY) News:
Below you will find a list of latest news for Roche Holding AG (RHHBY) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Roche Holding AG (RHHBY) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Roche Holding AG (RHHBY) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|